In addition to qPCR for monitoring BCR::ABL1, ABL1 kinase domain point mutation analysis provides important clinical information in predicting resistance and choosing appropriate tyrosine kinase inhibitor (TKI)/treatment strategies in chronic myeloid leukaemia (CML). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.